JMI Laboratories, North Liberty, Iowa, USA.
J Clin Microbiol. 2012 Nov;50(11):3694-702. doi: 10.1128/JCM.02024-12. Epub 2012 Sep 12.
A total of 434 methicillin-resistant Staphylococcus aureus (MRSA) baseline isolates were collected from subjects enrolled in a prospective, double-blind randomized trial comparing linezolid versus vancomycin for the treatment of nosocomial pneumonia. Isolates were susceptibility tested by broth microdilution, examined for inducible clindamycin resistance by D-test, and screened for heterogeneous resistance to vancomycin (hVISA) by the Etest macromethod. All strains were subjected to Panton-Valentine leukocidin (PVL) screening, and SCCmec, pulsed-field gel electrophoresis (PFGE), and spa typing. Selected strains were evaluated by multilocus sequence typing (MLST). Clonal complexes (CCs) were assigned based on the spa and/or MLST results. Most strains were CC5 (56.0%), which originated from North America (United States) (CC5-MRSA-SCCmec II/IV; 70.0%), Asia (CC5-MRSA-II; 14.0%) and Latin America (CC5-MRSA-I/II; 12.3%). The second- and third-most-prevalent clones were CC8-MRSA-IV (23.3%) and CC239-MRSA-III (11.3%), respectively. Furthermore, the CC5-MRSA-I/II clone predominated in Asia (50.7% within this region) and Latin America (66.7%), followed by CC239-MRSA-III (32.8% and 28.9%, respectively). The European strains were CC8-MRSA-IV (34.5%), CC22-MRSA-IV (18.2%), or CC5-MRSA-I/II/IV (16.4%), while the U.S. MRSA isolates were CC5-MRSA-II/IV (64.4%) or CC8-MRSA-IV (28.8%). Among the U.S. CC8-MRSA-II/IV strains, 73.7% (56/76 [21.2% of all U.S. MRSA strains]) clustered within USA300. One strain from the United States (USA800) was intermediate to vancomycin (MIC, 4 μg/ml). All remaining strains were susceptible to linezolid, daptomycin, vancomycin, and teicoplanin. hVISA strains (14.5%) were predominantly CC5-MRSA-II, from South Korea, and belonged to a single PFGE type. Overall, each region had two predominant clones. The USA300 rate corroborates previous reports describing increased prevalence of USA300 strains causing invasive infections. The prevalence of hVISA was elevated in Asia, and these strains were associated with CC5.
共有 434 株耐甲氧西林金黄色葡萄球菌(MRSA)基线分离株来自参加一项前瞻性、双盲随机试验的受试者,该试验比较了利奈唑胺与万古霉素治疗医院获得性肺炎的疗效。通过肉汤微量稀释法进行药敏试验,D 试验检测诱导型克林霉素耐药性,Etest 大方法筛选万古霉素异质性耐药(hVISA)。所有菌株均进行 Panton-Valentine 白细胞毒素(PVL)筛选,并进行 SCCmec、脉冲场凝胶电泳(PFGE)和 spa 分型。选择的菌株通过多位点序列分型(MLST)进行评估。根据 spa 和/或 MLST 结果确定克隆复合体(CC)。大多数菌株为 CC5(56.0%),来源于北美(美国)(CC5-MRSA-SCCmec II/IV;70.0%)、亚洲(CC5-MRSA-II;14.0%)和拉丁美洲(CC5-MRSA-I/II;12.3%)。第二和第三常见的克隆分别是 CC8-MRSA-IV(23.3%)和 CC239-MRSA-III(11.3%)。此外,CC5-MRSA-I/II 克隆在亚洲(该地区占 50.7%)和拉丁美洲(分别为 66.7%和 32.8%)占主导地位,其次是 CC239-MRSA-III(分别为 28.9%和 28.9%)。欧洲菌株为 CC8-MRSA-IV(34.5%)、CC22-MRSA-IV(18.2%)或 CC5-MRSA-I/II/IV(16.4%),而美国的 MRSA 分离株为 CC5-MRSA-II/IV(64.4%)或 CC8-MRSA-IV(28.8%)。在美国的 CC8-MRSA-II/IV 菌株中,73.7%(56/76 [所有美国 MRSA 菌株的 21.2%])聚类在美国 300 内。来自美国的一株菌株(USA800)对万古霉素呈中介(MIC,4μg/ml)。所有其余菌株对利奈唑胺、达托霉素、万古霉素和替考拉宁均敏感。hVISA 菌株(14.5%)主要为 CC5-MRSA-II,来自韩国,属于单一 PFGE 型。总体而言,每个地区都有两个主要的克隆。USA300 率证实了先前描述侵袭性感染中 USA300 菌株流行率增加的报道。亚洲的 hVISA 流行率升高,这些菌株与 CC5 相关。